1. Home
  2. BBD vs ILMN Comparison

BBD vs ILMN Comparison

Compare BBD & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banco Bradesco Sa

BBD

Banco Bradesco Sa

HOLD

Current Price

$3.95

Market Cap

36.4B

Sector

Finance

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$150.06

Market Cap

20.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBD
ILMN
Founded
1943
1998
Country
Brazil
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.4B
20.5B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
BBD
ILMN
Price
$3.95
$150.06
Analyst Decision
Strong Buy
Hold
Analyst Count
1
17
Target Price
N/A
$123.00
AVG Volume (30 Days)
29.6M
1.7M
Earning Date
02-05-2026
02-05-2026
Dividend Yield
4.35%
N/A
EPS Growth
47.11
N/A
EPS
0.38
4.46
Revenue
$16,507,289,161.00
$4,288,000,000.00
Revenue This Year
$78.18
N/A
Revenue Next Year
$7.75
$2.38
P/E Ratio
$9.66
$33.69
Revenue Growth
16.68
N/A
52 Week Low
$1.92
$68.70
52 Week High
$3.98
$155.53

Technical Indicators

Market Signals
Indicator
BBD
ILMN
Relative Strength Index (RSI) 75.39 61.31
Support Level $3.36 $137.00
Resistance Level $3.58 $155.53
Average True Range (ATR) 0.09 6.00
MACD 0.06 0.35
Stochastic Oscillator 97.10 74.38

Price Performance

Historical Comparison
BBD
ILMN

About BBD Banco Bradesco Sa

Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation—a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: